TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Thursday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of NASDAQ:TXMD opened at $1.58 on Thursday. The company has a 50 day moving average of $1.71 and a 200-day moving average of $1.87. TherapeuticsMD has a one year low of $1.43 and a one year high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.